Clinical Trial Update: A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Pneumococcal Conjugate Vaccine V114 to a marketed vaccine (V114-003) for Pneumococcal Infections; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Pneumococcal Conjugate Vaccine (V114) (Pneumococcal Conjugate Vaccine)
• V114-003

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-04-30